28443-52-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
N-(4-Chloro-3-hydroxyphenyl)acetamide is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new drugs and pesticides.
Used in Medical and Biotechnology Fields:
In the medical and biotechnology sectors, N-(4-Chloro-3-hydroxyphenyl)acetamide is utilized for its pharmacological and bioactive properties, which may lead to the discovery of new therapeutic agents and applications in biotechnological processes.
Used in Chemical Research and Development:
N-(4-Chloro-3-hydroxyphenyl)acetamide is employed as a building block in chemical research and development, where it aids in the creation of novel compounds with potential applications in various industries.

InChI:InChI=1/C8H8ClNO2/c1-5(11)10-6-2-3-7(9)8(12)4-6/h2-4,12H,1H3,(H,10,11)

Upstream product

• 6358-06-1 5-amino-2-chlorophenol 
• 108-24-7 acetic anhydride 

Downstream Products

• 38912-95-7 N-[3-(1-Amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracen-2-yloxy)-4-chloro-phenyl]-acetamide 
• 55302-69-7 C₁₈H₂₀ClN₃O₄ 
• 38920-03-5 N-{3-[1-Amino-9,10-dioxo-4-(toluene-4-sulfonylamino)-9,10-dihydro-anthracen-2-yloxy]-4-chloro-phenyl}-acetamide 
• 57838-70-7 N-{4-Chloro-6-[(Z)-2-chloro-4-methylamino-phenylimino]-3-oxo-cyclohexa-1,4-dienyl}-acetamide 
• 57839-22-2 N-[4-Chloro-2-(2-chloro-4-methylamino-phenylamino)-5-hydroxy-phenyl]-acetamide 
• 76464-54-5 4-chloro-3-isopropoxyaniline 
• 1349821-24-4 N-[4-chloro-3-(3-hydroxypropoxy)phenyl]acetamide 
• 1349820-48-9 6-chloro-3-ethyl-2-methyl-7-(2-phenoxyethoxy)-1H-quinolin-4-one 
• 1057218-21-9 4-chloro-3-methoxymethoxyphenylamine 
• 1341400-47-2 3-(5-amino-2-chlorophenoxy)propan-1-ol 
• 1349821-30-2 4-chloro-3-(2-morpholin-4-yl-ethoxy)phenylamine 
• 170230-17-8 N-[4-chloro-3-(2-dimethylaminoethoxy)phenyl]acetamide 
• 1349820-65-0 3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one 
• 1349820-87-6 6-butyl-2-methyl-3-(2-methyl-4-(4-(trifluoromethoxy)phenoxy)phenyl)-7-(2-phenoxyethoxy)quinolin-4(1H)-one 

Relevant academic research and scientific papers

4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a Plasmodium infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a Plasmodium infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time.

Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-Phenoxyethoxy)-4(1H)-quinolones

ICI 56,780 (5) displayed causal prophylactic and blood schizonticidal activity (ED50 = 0.05 mg/kg) in rodent malaria models but produced rapid acquisition of parasitological resistance in P. berghei infected mice. Herein we describe the synthesis of analogues of 5 with EC50 as low as 0.15 nM against multidrug resistant P. falciparum. Optimal activity with low cross-resistance indexes (RI) to atovaquone was achieved by introducing ortho-substituted aryl moieties at the 3-position of the 7-(2-phenoxyethoxy)- 4(1H)-quinolone core. (Figure presented

Optimization of 1,2,3,4-tetrahydroacridin-9(10 H)-ones as antimalarials utilizing structure-activity and structure-property relationships

Antimalarial activity of 1,2,3,4-tetrahydroacridin-9(10H)-ones (THAs) has been known since the 1940s and has garnered more attention with the development of the acridinedione floxacrine (1) in the 1970s and analogues thereof such as WR 243251 (2a) in the 1990s. These compounds failed just prior to clinical development because of suboptimal activity, poor solubility, and rapid induction of parasite resistance. Moreover, detailed structure-activity relationship (SAR) studies of the THA core scaffold were lacking and SPR studies were nonexistent. To improve upon initial findings, several series of 1,2,3,4-tetrahydroacridin-9(10H)-ones were synthesized and tested in a systematic fashion, examining each compound for antimalarial activity, solubility, and permeability. Furthermore, a select set of compounds was chosen for microsomal stability testing to identify physicochemical liabilities of the THA scaffold. Several potent compounds (EC50 100 nM) were identified to be active against the clinically relevant isolates W2 and TM90-C2B while possessing good physicochemical properties and little to no cross-resistance.

Oxidation dye for keratinic fibers containing 2-halo-5-acetaminophenol as a coupler

A dye composition for keratinic fibers comprising in combination: A. at least one oxidation base selected from the group consisting of an aromatic or heterocyclic compound carrying either two amino groups or one amine group and one hydroxy group, fixed in para position relative to each other on the aromatic or heterocyclic nucleus of said compound, said oxidation base being in the form of a free base or in the form of an acid addition salt thereof; and B. at least one coupler of the formula: SPC1 Wherein X represents a member selected from the group consisting of F, Cl or Br.